Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR

ACORDA THERAPEUTICS INC (ACOR)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/12/2018 06/13/2018 06/14/2018 06/15/2018 06/18/2018 Date
31.65(c) 31.65(c) 31.5(c) 31.15(c) 30.9 Last
678 436 658 162 509 152 1 537 643 101 972 Volume
-2.91% 0.00% -0.47% -1.11% -0.80% Change
More quotes
Financials (USD)
Sales 2018 347 M
EBIT 2018 13,0 M
Net income 2018 -68,4 M
Debt 2018 203 M
Yield 2018 -
Sales 2019 165 M
EBIT 2019 -115 M
Net income 2019 -141 M
Debt 2019 24,7 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 4,81x
EV / Sales2019 9,01x
Capitalization 1 466 M
More Financials
Company
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders.Its two main products are Ampyra and Zanaflex Capsules.The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis... 
Sector
Biotechnology & Medical Research
Calendar
06/27 | 04:00pmShareholder meeting
More about the company
Surperformance© ratings of Acorda Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACORDA THERAPEUTICS INC
01:01pACORDA THERAPEUTICS : to Present Data for INBRIJA™ (levodopa inhalation po..
BU
06/14ACORDA THERAPEUTICS : Patent Issued for Compositions and Methods of Using Chondr..
AQ
06/11ACORDA THERAPEUTICS INC : Today’s Research Reports on Stocks to Watch: Acorda Th..
AC
06/11ACORDA THERAPEUTICS : gains following Ampyra appeal arguments
AQ
06/07ACORDA THERAPEUTICS : Announces EMA Validation of the MAA Submission for INBRIJA..
AQ
05/29ACORDA THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (form ..
AQ
05/29ACORDA THERAPEUTICS : Announces EMA Validation of the MAA Submission for INBRIJA..
BU
05/10ACORDA THERAPEUTICS : Patent Issued for Therapeutic Dosing of a Neuregulin Or a ..
AQ
05/10ACORDA THERAPEUTICS : Provides Financial and Pipeline Update for First Quarter 2..
AQ
05/09ACORDA THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
AQ
More news
Sector news : Bio Therapeutic Drugs
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/01Lilly, Incyte Get FDA OK for Lower-Dose Rheumatoid Arthritis Drug
DJ
05/30Gap in regulating biotech drug copies prompts WHO to step in
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
01:00p$ACOR Acorda - Acorda to Present Data for INBRIJA™ (levodopa inhalation powde.. 
10:30aAcorda Therapeutics Inc $ACOR Major Shareholder Sells $6,858,694.20 in Stock .. 
06/17Acorda Therapeutics $ACOR Stock Rating Upgraded by BidaskClub  
06/17Zacks: Analysts Anticipate Acorda Therapeutics Inc $ACOR Will Announce Quarte.. 
06/16Acorda Therapeutics Inc $ACOR Insider Sells $108,899.94 in Stock  
More tweets
Qtime:110
News from SeekingAlpha
06/08Midday Gainers / Losers (06/08/2018) 
06/08HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (06/08/2018) 
06/08Acorda adds to rally, up 24% 
05/29EMA accepts Acorda's marketing application for Parkinson's med Inbrija 
05/03Acorda Therapeutics, Inc. 2018 Q1 - Results - Earnings Call Slides 
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Technical analysis trends ACORDA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 24,4 $
Spread / Average Target -22%
EPS Revisions
Managers
NameTitle
Ronald Cohen President, Chief Executive Officer & Director
Andrew R. Blight Chief Scientific Officer Emeritus
Richard P. Batycky Chief Technology Officer
Burkhard Blank Chief Medical Officer
Sandra Panem Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ACORDA THERAPEUTICS INC45.22%1 466
GILEAD SCIENCES-1.97%91 317
VERTEX PHARMACEUTICALS3.44%39 504
REGENERON PHARMACEUTICALS-16.13%33 406
NEUROCRINE BIOSCIENCES, INC.31.87%9 198
GENMAB-6.67%9 197